BeyondSpring Inc., a prominent biopharmaceutical company that is currently in the clinical stage, focuses on providing potential cancer therapies. The company, which comprises various subsidiaries, has recently been exploring the development of new cancer therapeutics. The company's leading asset is Plinabulin, a selective immune-modulating microtubule-binding agent that has entered the final phase of clinical trials for the prevention of chemotherapy-induced neutropenia, and to battle the later stages of non-small cell lung cancer. BeyondSpring also aims to use Plinabulin with various immuno-oncology agents, such as nivolumab, a PD-1 antibody, to target non-small cell lung cancer. Furthermore, the company seeks to use a CTLA-4 antibody called ipilimumab to improve the treatment of extensive-stage small cell lung cancer. Additionally, the company aims to harness the combined potential of PD-1, PD-L1 antibodies with radiation therapy to develop effective therapies for different types of cancer. Apart from this, BeyondSpring is also planning to develop three small molecule immune agents that are presently in preclinical stages, alongside a drug development platform. Since its inception in 2010, the company has been headquartered in New York, New York.
BeyondSpring, Inc.'s ticker is BYSI
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 51-200 employees working at BeyondSpring, Inc.
It is https://www.beyondspringpharma.com/index.aspx
BeyondSpring, Inc. is in the Healthcare sector
BeyondSpring, Inc. is in the Biotechnology industry
The following five companies are BeyondSpring, Inc.'s industry peers: